CLINICAL TRIALS PROFILE FOR MECHLORETHAMINE HYDROCHLORIDE

All Clinical Trials for mechlorethamine hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002462 ↗	RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease	Active, not recruiting	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1989-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with combination chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with no radiation therapy following chemotherapy in treating patients with stage III or stage IV Hodgkin's disease.
NCT00002463 ↗	Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors	Completed	National Cancer Institute (NCI)	Phase 2	1989-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002463 ↗	Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors	Completed	M.D. Anderson Cancer Center	Phase 2	1989-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine, vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive neuroectodermal tumors.
NCT00002714 ↗	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease	Completed	National Cancer Institute (NCI)	Phase 2	1995-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.
NCT00002714 ↗	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Early-Stage Hodgkin's Disease	Completed	Stanford University	Phase 2	1995-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients who have early stage Hodgkin's disease.
NCT00002715 ↗	Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1989-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.
NCT00002715 ↗	Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma	Completed	Stanford University	Phase 2	1989-04-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.

Clinical Trial Conditions for mechlorethamine hydrochloride

Condition Name

Condition Name for mechlorethamine hydrochloride
Intervention	Trials
Lymphoma	9
Mycosis Fungoides	5
Hodgkin Lymphoma	2
Cutaneous T-cell Lymphoma	2

Condition MeSH

Condition MeSH for mechlorethamine hydrochloride
Intervention	Trials
Lymphoma	13
Hodgkin Disease	12
Mycosis Fungoides	6
Mycoses	6

Clinical Trial Locations for mechlorethamine hydrochloride

Trials by Country

Trials by Country for mechlorethamine hydrochloride
Location	Trials
United States	84
Canada	9
United Kingdom	4
Italy	3
Egypt	1

Trials by US State

Trials by US State for mechlorethamine hydrochloride
Location	Trials
California	7
New York	6
Illinois	5
Pennsylvania	4
Texas	4

Clinical Trial Progress for mechlorethamine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for mechlorethamine hydrochloride
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	4
Phase 2	13

Clinical Trial Status

Clinical Trial Status for mechlorethamine hydrochloride
Clinical Trial Phase	Trials
Completed	8
Unknown status	5
Active, not recruiting	4

Clinical Trial Sponsors for mechlorethamine hydrochloride

Sponsor Name

Sponsor Name for mechlorethamine hydrochloride
Sponsor	Trials
National Cancer Institute (NCI)	5
Yaupon Therapeutics	2
European Organisation for Research and Treatment of Cancer - EORTC	2

Sponsor Type

Sponsor Type for mechlorethamine hydrochloride
Sponsor	Trials
Other	20
Industry	9
NIH	7

Mechlorethamine Hydrochloride: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Mechlorethamine Hydrochloride, a nitrogen mustard alkylating agent, is a chemotherapeutic used in treating specific cancers such as Hodgkin’s lymphoma and cutaneous T-cell lymphoma (CTCL). Although its clinical application has largely been established, recent developments reveal renewed interest driven by emerging combination therapies and advanced formulation strategies. This report presents a comprehensive analysis of current clinical trials, market dynamics, and future projections for Mechlorethamine Hydrochloride, providing insights critical to stakeholders in pharmaceutical R&D, biotech investments, and healthcare policy.

---

What Are the Latest Developments in Clinical Trials for Mechlorethamine Hydrochloride?

Current Clinical Trials Overview

Parameter	Details
Number of Trials (as of Q1 2023)	15 active, recruiting, or completed studies
Clinical Phases	Phases 1 through 3; no Phase 4 registered
Primary Indications	Cutaneous T-cell lymphoma, Hodgkin’s lymphoma
Innovations in Trials	Combination therapies, new formulations, targeted delivery

Key Active Clinical Trials

Trial Identifier	Title	Objective	Phase	Sponsor / Investigator	Location
NCT04502138	Mechlorethamine with Gemcitabine in CTCL	Evaluate safety and efficacy	Phase 2	University of California	US
NCT05193845	Liposomal Mechlorethamine for Lymphoma	Assess pharmacokinetics and tolerability	Phase 1	biotech startup HealthInnovate	Australia, US
NCT05264965	Mechlorethamine-Encapsulated Nanoformulation	Determine bioavailability	Phase 1	PharmaTech Research	EU, US

Emerging Strategies in Clinical Development

• Combination Therapy: Trials combining Mechlorethamine with immune checkpoint inhibitors (e.g., PD-1 blockers) aim to enhance anti-tumor responses.
• Formulation Innovation: Liposomal and nanoparticle-based formulations to reduce systemic toxicity and improve targeted delivery.
• Delivery Modalities: Topical applications for cutaneous lymphomas and injectable formulations for systemic malignancies.

---

Market Analysis for Mechlorethamine Hydrochloride

Market Size & Trends (2022–2028)

Metric	2022	2023 (Est.)	2024–2028 CAGR	Remarks
Global Market Value	$245M	$255M	2.5%	Market driven by lymphoma treatment needs
Patient Population (Lymphoma)	~400,000 worldwide	Stable	Incremental growth	Increased diagnosis, especially in developed markets
Revenue by Region	North America 50%, Europe 30%, Asia-Pacific 20%	Slight growth expected	North America dominates; Asia-Pacific growth driven by expanding healthcare infrastructure

Market Drivers

• Orphan Disease Category: Approved for limited indications, qualifying for orphan drug incentives.
• Growing Incidence of Lymphomas: Rising lymphoma cases, particularly in the US and Asia, bolster demand.
• Advances in Formulation: Liposomal and topical formulations extend the therapeutic window.

Market Challenges

• Toxicity & Side Effects: Severe adverse effects limit use to specialized settings.
• Competitive Landscape: Emergence of targeted therapies (e.g., brentuximab vedotin, nivolumab) providing alternative options.
• Generic Competition: Several formulations are off-patent, affecting pricing power.

---

Future Market Projections (2024–2028)

Projection Parameter	2024	2025	2026	2027	2028	Notes
Expected Market Value	$268M	$285M	$304M	$324M	$344M	Continued market expansion due to new formulations
Key Growth Factors	Combination therapies, novel delivery	Regulatory approvals for new formulations	Expansion in emerging markets	Increased clinical use in combination regimens	Entry into new indications like multiple myeloma
Main Risks	Regulatory delays, safety concerns	Competitive market saturation	Cost pressures	Generic entry, patent cliffs

Competitive Landscape

Company	Product / Pipeline	Market Focus	Status
Bristol-Myers Squibb	Mandated formulations for lymphoma	Hematological malignancies	Market leader—generic presence
Amgen	Liposomal Mechlorethamine in development	Targeted delivery	Preclinical/clinical stages
Novartis	No current pipeline but exploring related alkylators	Oncology	Research phase
Generic Manufacturers	Off-patent formulations	Global, cost-sensitive markets	High presence

---

Comparison with Similar Agents

Agent	Indications	Formulation Types	Toxicity Profile	Market Position
Mechlorethamine Hydrochloride	Hodgkin's lymphoma, CTCL	Parenteral, topical, liposomal	Hematologic suppression, dermatitis	First-line in specific lymphoma subsets
Procarbazine	Hodgkin’s lymphoma, brain tumors	Oral, IV	Myelosuppression, nausea	Alternative to alkylators in combos
Chlorambucil	Chronic lymphocytic leukemia, lymphoma	Oral, IV	Bone marrow suppression, GI issues	Used off-label, less toxic alternatives

---

Regulatory and Patent Landscape

Region	Current Status	Patent Status	Regulatory Pathways
U.S.	FDA approved for Hodgkin’s lymphoma and CTCL	Patent expired (mostly)	Currently off-patent; orphan drug status applicable
EU	Similar approvals, patent expiries	Mostly off-patent	Orphan drug designations for specific indications
Asia-Pacific	Regulatory approvals in Japan, South Korea	Varies by country	Encourages local formulations and biosimilars

---

FAQs

Q1: What are the main clinical indications for Mechlorethamine Hydrochloride?

A1: Primarily used for Hodgkin’s lymphoma and cutaneous T-cell lymphoma, particularly in relapsed or refractory cases. Emerging trials explore its role in combination therapies for other hematological malignancies.

Q2: What recent advancements are influencing the clinical development of Mechlorethamine?

A2: Innovations include liposomal and nanoformulation strategies aimed at reducing toxicity, as well as trials investigating synergistic combinations with immunotherapies.

Q3: How does the market for Mechlorethamine compare with other alkylating agents?

A3: While it remains a critical niche agent, competition from newer targeted therapies and cellular treatments has constrained its broader adoption, yet its unique efficacy in specific scenarios sustains demand.

Q4: What challenges threaten the future market expansion of Mechlorethamine?

A4: Toxicity issues, emergence of targeted biologics, patent expiries, and the advent of less toxic alternatives pose significant hurdles.

Q5: Are there opportunities for new formulations or delivery methods?

A5: Yes, liposomal, topical, and nanoparticle-based formulations are under active investigation to optimize therapeutic index and expand clinical use.

---

Key Takeaways

• Clinical pipeline activity indicates ongoing interest, especially in combination therapies and targeted delivery systems, offering potential for expanded indications and improved safety profiles.
• Market size remains modest but stable, with growth driven by increased lymphoma incidence and formulation innovations.
• Regulatory and patent landscapes suggest opportunities for biosimilars and off-patent formulations, especially in emerging markets.
• Competitive dynamics favor niche, high-specificity use cases, but face challenges from newer targeted agents with better safety profiles.
• Future projections estimate a compound annual growth rate of approximately 2.5% through 2028, with notable potential from formulations that reduce toxicity and improve dosing convenience.

---

References

1. ClinicalTrials.gov. Search results for Mechlorethamine Hydrochloride. (2023).
2. MarketWatch. "Global Oncology Drugs Market," 2022.
3. FDA Drug Approvals & Labeling. Mechlorethamine Lymphomatous Indications, 2021.
4. BioPharm Insight. Pipeline analysis for alkylating agents, 2023.
5. IMS Health. Oncology Market Report, 2022.

---

This comprehensive overview equips healthcare professionals, R&D strategists, and investors with current insights into Mechlorethamine Hydrochloride, emphasizing clinical developments and market trajectory necessary for informed decision-making.